Hosted on MSN3d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
Hosted on MSN6d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
GSK's Sinus Disease Drug Secures Approval In China
China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...
Pharmabiz5d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
Daily5d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
GSK's Nucala gets third approval in China
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...
The Pharma Letter6d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
pharmaphorum4y
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
Business Insider1mon
GSK: FDA Accepts For Review Submission For New Indication Of Nucala In COPD
and for adult patients with chronic rhinosinusitis with nasal polyps or CRSwNP and inadequate response to nasal corticosteroids. Nucala is currently not indicated for COPD anywhere in the world.
Pharmabiz29d
US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease
Nucala is currently approved for use in the US across four ... add-on maintenance treatment for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and inadequate response to nasal ...